Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02739412
Recruitment Status : Recruiting
First Posted : April 15, 2016
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
Michael Curry, Beth Israel Deaconess Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2019
  Estimated Study Completion Date : June 2020